BANGALORE, July 20 (Reuters) - Shares of Nucryst Pharmaceuticals Corp. (NCST.O: Quote, Profile, Research) doubled their value on Friday, a day after its antimicrobial cream received approval from U.S. health regulators.
The cream, a formulation of nanocrystalline silver NPI 32101, was previously being studied as a treatment for dermatitis but failed in a mid-stage trial in September 2006, prompting the company to discontinue further studies.
" ...it failed to show statistical significance as an anti-inflammatory (treatment), but we did know its antimicrobial properties prior to that," company spokesman David Wills said by phone.
After the failure of the trial, Nucryst focused on seeking approval for the product as a medical device that acts as a barrier to infection from a broad spectrum of microbes, Willis added.
Before today's gains, Nucryst shares had lost about 80 percent of their value since the failure of the trial.
The company has not determined the timing of the product's launch, Nucryst said in a statement.
Shares of the company were up $2.28 at $4.54 in midday trade, making it the highest percentage gainer on the Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore)
Recent WEDXF News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/08/2024 09:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 12:06:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/21/2023 11:59:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/21/2023 11:55:51 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM